Details of HLA and HCV RNA status of HLA-A*03-positive patients included in the study
| Patient no.* | HLA class I | HLA class II | HCV RNA status | A*03 assays (tetramer frequency %) | Sequence |
| 15 | A*03,03,B*07,44, C*07,16 | DR*1501,1302 DQ*0602,0609 | PCR+ | Culture (neg) | TVYHGAGSK |
| 1537 | A*01,03,B*07,08 C*07,08 | DR*1501, 1501, DQ*0602, 0602 | PCR+ | TVYHGAGAR | |
| 39 | A*01,03,B*37,57, C*06,06 | DR*0701,0101, DQ*0501,3032 | PCR+ | TVYHGAGAR | |
| 1543 | A*03,24,B*35,51, C*04,17 | DR*0407,1601, DQ*0301,0501 | PCR+ | TVYHGAGAR | |
| 77 | A*01,03,B*07,08, C*07,07 | DR*3011,1501, DQ*0201,0602 | PCR+ | TVYHGAGAR | |
| 60 | A*02,03,B*07,44, C*05,07 | DR*4048,4013, DQ*0301,0302 | PCR −ve (Treated) | Culture (14.1%) | TVYHGAGTR |
| 1548 | A*02,03,B*14,18, C*07,08 | DR*401,1104, DQ*0301,0301 | PCR+ | TVYHGAGAR | |
| 1549 | A03,23,B*07,47, C*04,07 | DR701,1501, DQ*0202,0602 | PCR+ | TVYHGAGAR | |
| 1552 | A*03,30,B*17,18, C*05,07 | DR*3011,1501, DQ*0201,0602 | PCR+ | TVYHGAGTK | |
| 1562 | A*03,30,B*13,44, C*06,16 | DR*0701,0701, DQ*0202,0202 | PCR+ | XXYHGAGTR | |
| 1571 | A*02,03,B*14,57, C*08,10 | DR*1501,1301, DQ*0602,0603 | PCR+ | TVYHGAGTK | |
| 1587 | A*02,03,B*14,57, C*06,08 | DR*0701,1303, DQ*0301,3023 | PCR+ | TVYHGAGTR | |
| 106 | A*01,03,B*14,37, C*06,08 | DR*0401,1201, DQ*0301,0609 | SR | Culture (3.9%) | – |
| 49 | A*03,68,B*07,15, C*06,07 | DR*3011,0701, DQ*0602,0302 | SR | Culture (6.8%), Elispot | – |
| 29 | A*01,03,B*07,57, C*06,07 | DR*3011,0701, DQ*0201,3032 | SR | Culture (4.4%), Elispot | – |
| 113 | A*01,03,B*07,08, C*07,08 | DR*1501,1501, DQ*0602,0602 | PCR+ | Culture (neg) | – |
| 105 | A*03,26,B*27,49, C*01,07 | DR*101,1101, DQ*0301,0501 | SR | Culture (neg) | – |
| 102 | A*02,03,B*14,44,C*05,08 | DR*0101,0404, DQ*0501,0302 | SR | Culture (neg) | – |
| 110 | A*02,03,B*14,44, C*05,08 | DR*0401,0101, DQ*0301,0302 | SR | Culture (2.83%) | – |
| 109 | A*02,03,B*07,44, C*05,07 | DR*0401,0401, DQ*0301,0302 | SR | Culture (1.36%) | – |
| 40 | A*02,03,B*14,60, C*08,10 | DR*1501,1501, DQ*0602,0602 | SR | Elispot | – |
| 42 | A*01,03,B*07,57, C*06,07 | DR*1501101, DQ*0602,0501 | SR | Elispot | – |
| 50 | A*02,03,B*07,44, C*05,07 | DR*1501101, DQ*0602,0501 | SR | Elispot | – |
| 52 | A*01,03,B*07,07, C*07,07 | DR*0101,0404, DQ*0501,0302 | SR | Elispot |
HCV, hepatitis C virus; HLA, human leucocyte antigen; SR, spontaneous resolver. Class II alleles are DRB1 or DQB1.